Publ3 search

Z6_60GI02O0O8IDC0QEJUJ26TJDI4

Error:

Javascript is disabled in this browser. This page requires Javascript. Modify your browser's settings to allow Javascript to execute. See your browser's documentation for specific instructions.

Publikační činnost

Probíhá načítání, čekejte prosím...

Record type:	stať ve sborníku (D)
Home Department:	Katedra interních oborů (11300)
Title:	PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE
Citace	Janíková, A., Chaloupková, R., Campr, V., Kopalová, N., Klener, P., Benešová, K., Hamouzová, J., Belada, D., Sykorová, A., Procházka, V., Pirnos, J., Ďuraš, J., Mociková, H., Michalka, J. a Trněný, M. PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE. In: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi: 2020-06-18 Lugano, Switzerland. s. 413-414. ISSN 1099-1069.

Subtitle
Publication year:	2019
Obor:	Onkologie a hematologie
Number of pages:	1
Page from:	413
Page to:	414
Form of publication:	Tištená verze
ISBN code:	neuvedeno
ISSN code:	1099-1069
Proceedings title:
Proceedings:	Mezinárodní
Publisher name:	neuvedeno
Place of publishing:	neuvedeno
Country of Publication:	Sborník vydaný v zahraničí
Název konference:	15th International Conference on Malignant Lymphoma Palazzo dei Congressi
Conference venue:	Lugano, Switzerland
Datum zahájení konference:
Typ akce podle státní příslušnosti účastníků:	Celosvětová akce
WoS code:
EID:

Key words in English:	diffuse large B?cell lymphoma (DLBCL); immunochemotherapy; prognostic indices.
Annotation in original language:	Patients with relapsed/progressed diffuse large B‐cell lymphoma (rDLBCL) survive globally with median 12 months since relapse and majority of deaths is attributed to lymphoma. There is urgent need of efficient therapy for rDLBCL, but clinical trials cannot find efficient therapy up to now. Regardless the selection bias of inclusion/exclusion criteria in clinical trials, time to therapy initiation seems to be a critical point for the trial enrollment
Annotation in english language:

References

Reference

R01:

Complementary Content

${loading}